Identifying the Determinants of Adjuvant Hormonal Therapy Medication taking Behaviour in Women with Stage I-III Breast Cancer: a Systematic Review and Meta-analysis

December 1, 2015

Patient Education and Counseling, Vol. 98, Issue 12, December, 2015, pp. 1524-1539

Objective:

This systematic review and meta-analysis aimed to identify the modifiable determinants of adjuvant hormonal therapy medication taking behaviour (MTB) in women with stage I-III breast cancer in clinical practice settings.

Methods:

We searched PubMed EMBASE, PsycINFO and CINAHL for articles investigating determinants of adjuvant hormonal therapy. Potentially modifiable determinants were identified and mapped to the 14 domains of the Theoretical Domains Framework (TDF), an integrative framework of theories of behavioural change. Meta-analysis was used to calculate pooled odds ratios for selected determinants.

Results:

Potentially modifiable determinants were identified in 42 studies and mapped to 9 TDF domains. In meta-analysis treatment side-effects (Domain: Beliefs about Capabilities) and follow-up care with a general practitioner (vs. oncologist) (Social Influences) were significantly negatively associated with persistence (p < 0.001) and number of medications (Behaviour Regulation) was significantly positively associated with persistence (p < 0.003). Studies did not examine several domains (including Beliefs about Consequences, Intentions, Goals, Social Identity, Emotion and Knowledge) which have been reported to influence MTB in other disease groups.

Conclusions:

There is some evidence that the domains Beliefs about Capabilities, Behaviour Regulation and Social Influences influence hormonal therapy MTB.

Practice implications:

Further research is needed to develop effective interventions to improve hormonal therapy MTB.